Adial Pharmaceuticals, Inc.

Overview

• Clinical-stage biopharmaceutical company developing therapies for addiction and related disorders, with an emphasis on Alcohol Use Disorder (AUD).
• Lead product candidate: AD04, which uses ondansetron as the active pharmaceutical ingredient to treat AUD in genetically defined (biomarker-positive) patient subgroups.
• AD04 is paired with a companion diagnostic genetic test to identify patients most likely to respond. The goal is to reduce heavy drinking and related risks without requiring complete abstinence.
• The company plans to advance regulatory filings in the US and Europe/UK and to pursue additional indications through lifecycle expansions if AD04 is approved.

Product development and regulatory status

• AD04 mechanism: ondansetron-based therapy dosed to a low, chronic level and targeted to specific serotonin receptor gene variants (for example, HTR3A/HTR3B genotypes).
• Companion diagnostic: a genetic test intended to identify genotype-positive patients most likely to benefit; regulatory considerations include PMA/510(k) pathways for the diagnostic device.
• Clinical program:
  • ONWARD Phase 3 trial completed with 302 patients enrolled (plus one screen that did not initiate treatment) across 25 sites in Sweden, Finland, Poland, Latvia, Bulgaria, and Croatia.
  • Topline results showed a statistically significant signal in the pre-specified heavy drinking subgroup, with safety and tolerability similar to placebo. The trial did not meet the primary endpoint in the overall population.
• Regulatory path:
  • US: pursuing an adaptive enrichment Phase 3 design and engaged with the FDA, with consideration of a one-study framework. Planned program includes one Phase 3 trial with enrichment, plus a confirmatory trial and an open-label safety extension, subject to regulatory feedback.
  • Europe/UK: initial regulatory discussions completed in 2023; primary focus remains on the US program with potential international expansion.

Intellectual property

• Exclusive license from the University of Virginia Licensing & Venture Group (UVA LVG) covering multiple patent families for AD04, including associated data and know-how from the UVA program.
• Adial filed a provisional PCT application in 2025 intended to extend core AD04 protection to 2045 if granted.
• Licensed patents cover specific uses of ondansetron for targeted AUD genotypes and include royalty and milestone arrangements.

Key assets and partnerships

• UVA LVG license:
  • Exclusive worldwide rights to AD04-related patents and data.
  • Financial terms include issuance of 4% of Adial equity as Class A units (convertible to common stock), annual minimum royalties starting at $40,000, milestone payments (examples: $20,000; $155,000; $275,000; $1,000,000 upon approval), and royalties of 2% in countries with patent coverage or 1% in countries without. Sublicensing income share is 15%.
  • Term runs to patent expiry, with perpetual, royalty-free rights after expiration or abandonment of the licensed patents.
• Molteni Farmaceutici collaboration framework (announced March 3, 2026):
  • Proposed exclusive partnership framework to commercialize AD04 in Europe, subject to a definitive agreement.
  • Framework contemplates upfront payments, development and milestone payments, and tiered royalties on European net sales; potential total value estimated near $60 million in royalties and milestones if development and commercialization progress.
  • Molteni has an exclusivity period to evaluate feasibility and plan a market launch; there is no obligation to enter into a definitive agreement.
• Adial-owned patent activity:
  • July 2025 update to a provisional patent filing aimed at extending core AD04 protection to 2045 if granted.

Financial snapshot

• Revenue: No product revenues to date.
• Employees: 6 total (5 full-time, 1 consultant). The Chief Medical Officer serves as a consultant at approximately 50% time.
• Net losses:
  • 2025: Approximately $8.0 million net loss.
  • 2024: Approximately $13.2 million net loss.
• Accumulated deficit: Approximately $90.0 million as of December 31, 2025; approximately $82.0 million as of December 31, 2024.
• Cash runway: Current cash and cash equivalents are not expected to be sufficient to fund operations for the next 12 months from the filing date.
• Recent financing: Approximately $8.5 million net proceeds from equity sales and warrant exercises to support AD04 development.
• Liquidity and capital needs: The company intends to raise additional financing (equity, debt, grants, or collaborations) to fund ongoing and planned clinical development and potential regulatory and commercial activities.
• Stock actions: A 1-for-25 reverse stock split was effected on February 5, 2026; Nasdaq indicated the company regained the minimum bid price as of February 23, 2026. The company continues to face Nasdaq compliance considerations and liquidity risks if price or market capitalization remain weak.

Corporate strategy and market context

• Two-track approach: (1) advance AD04 through the US regulatory pathway using an adaptive enrichment Phase 3 design; (2) selectively pursue international (EU/UK) development and partnering opportunities, using collaborations such as the Molteni framework to support development and commercialization outside the United States.
• Regulatory considerations: the company is focused on evolving FDA guidance and other regulatory requirements, including companion diagnostic approvals and post-approval obligations.
• Market context: the AUD treatment landscape is largely focused on abstinence-based therapies with safety and tolerability concerns. AD04 aims to offer a harm-reduction approach with a favorable safety profile; market acceptance will depend on regulatory outcomes, payer coverage, and clinician adoption.

Summary

• Adial is developing AD04 (ondansetron) for genotype-positive AUD, paired with a companion diagnostic test to identify likely responders.
• There are no approved products or product revenues to date. Major development, regulatory, and commercialization milestones remain ahead.
• The company relies on partnerships and licensing, notably the UVA LVG license and a proposed Molteni collaboration for European commercialization.
• Funding remains a critical ongoing constraint. The company operates with a small team and has incurred substantial cumulative losses, with a single-digit million capital runway and plans to raise additional funds as needed.